Curated News
By: NewsRamp Editorial Staff
June 02, 2025
Telomir Pharmaceuticals to Present at BIO International Convention 2025, Plans IND Application for Telomir-1
TLDR
- Telomir Pharmaceuticals to explore licensing, M&A, and collaborations at BIO International Convention 2025, gaining competitive edge.
- Telomir-1, a small molecule by Telomir Pharma, aims to elongate telomeres and treat various diseases with novel clinical endpoints.
- Telomir Pharma's Telomir-1 seeks FDA guidance for accelerated development to promote longevity and improve quality of life for humans and animals.
- Telomir Pharma's participation in BIO International Convention 2025 highlights innovative approach to addressing degenerative and age-related diseases.
Impact - Why it Matters
This news highlights Telomir Pharmaceuticals' advancements in developing a potential anti-aging treatment with broad therapeutic applications. Investors and individuals interested in longevity science and innovative pharmaceuticals should pay attention to Telomir's progress and potential impact on future healthcare solutions.
Summary
Telomir Pharmaceuticals (NASDAQ: TELO) announced its participation in the BIO International Convention 2025 to explore licensing, M&A, and strategic collaborations. The company is preparing to submit an IND application for Telomir-1, a small molecule targeting aging mechanisms across various diseases. Telomir aims to initiate first-in-human dosing in 2026 and seeks FDA guidance on novel clinical endpoints.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Telomir Pharmaceuticals to Present at BIO International Convention 2025, Plans IND Application for Telomir-1
